These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 21292829)
21. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027 [TBL] [Abstract][Full Text] [Related]
22. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758 [TBL] [Abstract][Full Text] [Related]
23. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Veilleux A; Houde VP; Bellmann K; Marette A Mol Endocrinol; 2010 Apr; 24(4):766-78. PubMed ID: 20203102 [TBL] [Abstract][Full Text] [Related]
24. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Ning J; Clemmons DR Mol Endocrinol; 2010 Jun; 24(6):1218-29. PubMed ID: 20363874 [TBL] [Abstract][Full Text] [Related]
25. Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Kang NH; Hwang KA; Lee HR; Choi DW; Choi KC Food Chem Toxicol; 2013 Sep; 59():373-9. PubMed ID: 23810794 [TBL] [Abstract][Full Text] [Related]
26. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100 [TBL] [Abstract][Full Text] [Related]
27. RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1. Gustafsson N; Zhao C; Gustafsson JA; Dahlman-Wright K Cancer Res; 2010 Feb; 70(3):1265-74. PubMed ID: 20103625 [TBL] [Abstract][Full Text] [Related]
28. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235 [TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Gao S; Duan C; Gao G; Wang X; Yang H Int J Biochem Cell Biol; 2015 Jul; 64():25-33. PubMed ID: 25813876 [TBL] [Abstract][Full Text] [Related]
31. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Pearce LR; Alton GR; Richter DT; Kath JC; Lingardo L; Chapman J; Hwang C; Alessi DR Biochem J; 2010 Oct; 431(2):245-55. PubMed ID: 20704563 [TBL] [Abstract][Full Text] [Related]
32. Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Huderson BP; Duplessis TT; Williams CC; Seger HC; Marsden CG; Pouey KJ; Hill SM; Rowan BG Endocrinology; 2012 Sep; 153(9):4144-59. PubMed ID: 22733972 [TBL] [Abstract][Full Text] [Related]
33. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells. Zhang S; Li X; Burghardt R; Smith R; Safe SH J Mol Endocrinol; 2005 Dec; 35(3):433-47. PubMed ID: 16326831 [TBL] [Abstract][Full Text] [Related]
34. Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells. Wang LM; Xie KP; Huo HN; Shang F; Zou W; Xie MJ Asian Pac J Cancer Prev; 2012; 13(4):1431-7. PubMed ID: 22799344 [TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line. Eertmans F; Dhooge W; De Wever O; Bracke M; Comhaire F; Kaufman JM J Cell Physiol; 2007 Sep; 212(3):583-90. PubMed ID: 17458895 [TBL] [Abstract][Full Text] [Related]
36. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation. Al-Dhaheri MH; Rowan BG Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199 [TBL] [Abstract][Full Text] [Related]
37. Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. Tian J; Berton TR; Shirley SH; Lambertz I; Gimenez-Conti IB; DiGiovanni J; Korach KS; Conti CJ; Fuchs-Young R J Clin Invest; 2012 Jan; 122(1):192-204. PubMed ID: 22182837 [TBL] [Abstract][Full Text] [Related]
38. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. Byfield MP; Murray JT; Backer JM J Biol Chem; 2005 Sep; 280(38):33076-82. PubMed ID: 16049009 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Rosenblatt AE; Garcia MI; Lyons L; Xie Y; Maiorino C; Désiré L; Slingerland J; Burnstein KL Endocr Relat Cancer; 2011 Apr; 18(2):207-19. PubMed ID: 21118977 [TBL] [Abstract][Full Text] [Related]
40. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Khamzina L; Veilleux A; Bergeron S; Marette A Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]